JP2014509637A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509637A5
JP2014509637A5 JP2014501722A JP2014501722A JP2014509637A5 JP 2014509637 A5 JP2014509637 A5 JP 2014509637A5 JP 2014501722 A JP2014501722 A JP 2014501722A JP 2014501722 A JP2014501722 A JP 2014501722A JP 2014509637 A5 JP2014509637 A5 JP 2014509637A5
Authority
JP
Japan
Prior art keywords
compound
formula
medicament
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014501722A
Other languages
English (en)
Other versions
JP5826374B2 (ja
JP2014509637A (ja
Filing date
Publication date
Priority claimed from GBGB1105659.5A external-priority patent/GB201105659D0/en
Application filed filed Critical
Publication of JP2014509637A publication Critical patent/JP2014509637A/ja
Publication of JP2014509637A5 publication Critical patent/JP2014509637A5/ja
Application granted granted Critical
Publication of JP5826374B2 publication Critical patent/JP5826374B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. 式(Ia):
    Figure 2014509637

    で表される化合物又はその薬学的に許容しうるエステルもしくは塩。
  2. 式(Ib):
    Figure 2014509637

    で表される化合物である、請求項1に記載の化合物。
  3. 式(Ic):
    Figure 2014509637

    で表される化合物である、請求項1に記載の化合物。
  4. 式(Ia)の化合物が、式(Ib)の化合物と(Ic)の化合物の混合物を含む、請求項1に記載の化合物。
  5. 式(Ia)の化合物が、式(Ib)の化合物と(Ic)の化合物のラセミ混合物を含む、請求項4に記載の化合物。
  6. 式(Ia)の化合物が、エナンチオマー過剰式(Ib)の化合物を含む、請求項4に記載の化合物。
  7. 式(Ia)の化合物が、エナンチオマー過剰式(Ic)の化合物を含む、請求項4に記載の化合物。
  8. 請求項1〜7のいずれか一項に請求される少なくとも1つの化合物、及び場合により、1つ又は複数の薬学的に許容しうる賦形剤を含む、医薬組成物。
  9. 治療において使用するための、請求項1〜8のいずれか一項に記載の化合物又は組成物。
  10. カリウムチャネル阻害において使用するための、請求項1〜8のいずれか一項に記載の化合物又は組成物。
  11. 不整脈の治療又は予防において使用するための化合物又は組成物である、請求項10に記載の化合物又は組成物。
  12. カリウムチャネル阻害において使用するための医薬を製造するための、請求項1〜7のいずれか一項に記載の化合物の使用。
  13. 医薬が、不整脈の治療又は予防において使用するための医薬である、請求項12に記載の使用。
JP2014501722A 2011-04-01 2012-03-29 チエノ[2,3−d]ピリミジン誘導体及び不整脈を処置するためのそれらの使用 Expired - Fee Related JP5826374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1105659.5 2011-04-01
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (3)

Publication Number Publication Date
JP2014509637A JP2014509637A (ja) 2014-04-21
JP2014509637A5 true JP2014509637A5 (ja) 2015-07-23
JP5826374B2 JP5826374B2 (ja) 2015-12-02

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501722A Expired - Fee Related JP5826374B2 (ja) 2011-04-01 2012-03-29 チエノ[2,3−d]ピリミジン誘導体及び不整脈を処置するためのそれらの使用

Country Status (42)

Country Link
US (1) US9249155B2 (ja)
EP (1) EP2694518B1 (ja)
JP (1) JP5826374B2 (ja)
KR (1) KR20140023332A (ja)
CN (1) CN103492392B (ja)
AP (1) AP2013007198A0 (ja)
AR (1) AR088735A1 (ja)
AU (1) AU2012235882B2 (ja)
BR (1) BR112013025236A2 (ja)
CA (1) CA2831493A1 (ja)
CL (1) CL2013002789A1 (ja)
CO (1) CO6801756A2 (ja)
CR (1) CR20130488A (ja)
CU (1) CU24173B1 (ja)
CY (1) CY1117025T1 (ja)
DK (1) DK2694518T3 (ja)
EA (1) EA201301111A1 (ja)
EC (1) ECSP13012988A (ja)
ES (1) ES2558563T3 (ja)
GB (1) GB201105659D0 (ja)
GT (1) GT201300225A (ja)
HK (2) HK1193096A1 (ja)
HR (1) HRP20151340T1 (ja)
HU (1) HUE028438T2 (ja)
IL (1) IL228555A0 (ja)
MA (1) MA35064B1 (ja)
ME (1) ME02314B (ja)
MX (1) MX335937B (ja)
NI (1) NI201300100A (ja)
PE (1) PE20141021A1 (ja)
PL (1) PL2694518T3 (ja)
PT (1) PT2694518E (ja)
RS (1) RS54458B1 (ja)
RU (1) RU2013148627A (ja)
SG (1) SG193578A1 (ja)
SI (1) SI2694518T1 (ja)
SM (1) SMT201500322B (ja)
TN (1) TN2013000377A1 (ja)
TW (1) TWI516265B (ja)
UA (1) UA110131C2 (ja)
WO (1) WO2012131379A1 (ja)
ZA (1) ZA201307085B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150307532A1 (en) * 2012-11-20 2015-10-29 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
MX2019014875A (es) * 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
WO1997007119A1 (en) 1994-08-26 1997-02-27 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
ATE242230T1 (de) 1996-07-26 2003-06-15 Nissan Chemical Ind Ltd Chroman derivate
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク. カリウムチャネル阻害剤
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
EP1214307B1 (en) 1999-09-24 2004-04-07 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6677371B1 (en) 1999-10-05 2004-01-13 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6458794B2 (en) 1999-12-21 2002-10-01 Icagen, Inc. Potassium channel inhibitors
WO2002024655A1 (en) 2000-09-20 2002-03-28 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
KR20030071880A (ko) 2001-02-02 2003-09-06 메르크 파텐트 게엠베하 피라졸로[4,3-d]피리미딘과 엔도델린 수용체 길항제또는 티에노피리미딘과 엔도델린 수용체 길항제를포함하여 이루어지는 약제학적 조성물
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
KR100869897B1 (ko) 2001-06-25 2008-11-24 닛산 가가쿠 고교 가부시키 가이샤 부정맥 치료용 치환 벤조피란 유도체
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
CN1823071B (zh) * 2003-06-11 2012-12-19 润生有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1845918A (zh) * 2003-07-02 2006-10-11 沃泰克斯药物股份有限公司 可用作电压-门控离子通道调节剂的嘧啶
JP2007517793A (ja) 2004-01-06 2007-07-05 大正製薬株式会社 環状アミノ基によって置換されたチエノピリミジン及びチエノピリジン誘導体
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
WO2007146284A2 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Similar Documents

Publication Publication Date Title
JP2013032389A5 (ja)
JP2013518107A5 (ja)
JP2014507446A5 (ja)
JP2013509429A5 (ja)
JP2015078230A5 (ja)
JP2013542247A5 (ja)
JP2017524735A5 (ja)
JP2016534063A5 (ja)
JP2015501783A5 (ja)
JP2014521735A5 (ja)
JP2015516419A5 (ja)
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2017514910A5 (ja)
JP2016510326A5 (ja)
JP2010521516A5 (ja)
JP2015509075A5 (ja)
JP2016537338A5 (ja)
JP2016532632A5 (ja)
PH12015501945B1 (en) Formulations of organic compounds
JP2016515550A5 (ja)
JP2013513607A5 (ja)
JP2014148552A5 (ja)
JP2014509637A5 (ja)
JP2010500284A5 (ja)
JP2015509917A5 (ja)